Regeneron Pharmaceuticals’s Intellia Therapeutics NTLA Stock Holding History

Regeneron Pharmaceuticals’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.7M	Hold	3,702,995	–	–	35.35%	2
2026 Q1	$47.5M	Hold	3,702,995	–	–	99.14%	1
2025 Q4	$33.3M	Hold	3,702,995	–	–	98.49%	1
2025 Q3	$64M	Hold	3,702,995	–	–	9.13%	2
2025 Q2	$34.7M	Hold	3,702,995	–	–	2.34%	2
2025 Q1	$26.3M	Hold	3,702,995	–	–	2.13%	2
2024 Q4	$43.2M	Buy	+3,702,995	New	+$57.8M	3.94%	2

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regeneron Pharmaceuticals's NTLA Position: Q2 2026 in Review

Regeneron Pharmaceuticals held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 3,702,995 shares worth $62.7M. The position accounts for 35.35% of the portfolio, ranked #2.

Regeneron Pharmaceuticals first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $64M in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Regeneron Pharmaceuticals held 3,702,995 shares of Intellia Therapeutics worth $62.7M as of Q2 2026.
Regeneron Pharmaceuticals left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 35.35% of Regeneron Pharmaceuticals's portfolio in Q2 2026, its #2 holding.
Regeneron Pharmaceuticals first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
Regeneron Pharmaceuticals's Intellia Therapeutics position peaked at $64M in Q3 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2026, filed 7 Aug 2026.